Meningococcal Disease
📧 Sign up to get email alerts when something new happens for Meningococcal Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. [Phase 2]
Phase 2 feasibility study of GSK's GSK2202083A vaccine in healthy infants at 3, 5, and 11 months was terminated, with results posted in 2017…
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children [Phase 3]
Phase 3 safety study results completed for combination vaccines Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY in child…
-
CLINICAL_TRIALS trial_result · 2017-03-14Clinical Trial Update: Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years [Phase 4]
Phase 4 trial update assessing the safety of a serogroups ACWY meningococcal vaccine in about 3,000 Filipino subjects over age 2.
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects [Phase 3]
A Phase 3 trial update evaluating DTPw-HBV/Hib at 15-18 months followed by Mencevax ACWY at 24-30 months in primed subjects; the study is co…
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old [Phase 2]
Phase 2 study evaluating the safety and immunogenicity of a single dose of GSK134612 in children aged 12-14 months and 3-5 years, with resul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. [Phase 3]
Phase 3 trial evaluating safety and immunogenicity of the Novartis Meningococcal B Vaccine in immunocompromised children and adolescents com…
-
CLINICAL_TRIALS trial_result · 2016-12-01Clinical Trial Update: Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents [Phase 2]
A Phase 2 study evaluated the safety and immune response of two serogroup B meningococcal vaccines in healthy adolescents; the trial has com…
-
CLINICAL_TRIALS withdrawal · 2016-12-01Clinical Trial Update: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older
The clinical trial evaluating the safety of a single-dose meningococcal ACWY conjugate vaccine in subjects aged 2 years and older has been w…
-
CLINICAL_TRIALS trial_result · 2016-11-30Clinical Trial Update: Understanding the Immune Response to Two Different Meningitis Vaccines [Phase 4]
Phase 4 trial update examining the immune responses elicited by two different meningitis vaccines and how they target meningitis, meningococ…
-
CLINICAL_TRIALS trial_result · 2016-10-25Clinical Trial Update: Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180) [Phase 2]
This Phase 2 extension study evaluated the safety and immunogenicity of a booster dose of the MenABCWY meningococcal vaccine given 24 months…
-
CLINICAL_TRIALS research · 2016-09-29Clinical Trial Update: Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age [Phase 1, Phase 2]
This clinical trial update reports on the immunogenicity and safety of a combined meningococcal A/C and Haemophilus influenzae type b conjug…
-
CLINICAL_TRIALS trial_result · 2016-09-21Clinical Trial Update: Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine [Phase 3]
A Phase 3 immunogenicity study comparing GlaxoSmithKline's Hib-MenC conjugate vaccine to a licensed meningococcal C vaccine; it assesses pri…
-
CLINICAL_TRIALS trial_result · 2016-09-21Clinical Trial Update: Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 [Phase 3]
Phase 3 safety, reactogenicity and immunogenicity study evaluating a booster dose of Hib-MenC given with Priorix in toddlers previously prim…
-
CLINICAL_TRIALS trial_result · 2016-09-21Clinical Trial Update: Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs [Phase 2]
Phase 2 trial by GlaxoSmithKline evaluating four formulations of a meningococcal A,C,W-135,Y conjugate vaccine given as a single dose to hea…
-
CLINICAL_TRIALS trial_result · 2016-09-16Clinical Trial Update: Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs [Phase 2]
Phase 2 trial evaluating the immunogenicity and safety of a meningococcal serogroup B vaccine given in a 3-dose schedule to healthy adolesce…
-
CLINICAL_TRIALS trial_result · 2016-09-16Clinical Trial Update: Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers [Phase 2]
Phase 2 study completed assessing GlaxoSmithKline's MenC-TT and Hib-MenC-TT (Meningitec) vaccines in healthy toddlers.
-
CLINICAL_TRIALS trial_result · 2016-09-16Clinical Trial Update: Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants [Phase 2]
A Phase 2 study evaluating GlaxoSmithKline's MenC-TT and Hib-MenC-TT vaccines in infants has completed.
-
CLINICAL_TRIALS trial_result · 2016-09-16Clinical Trial Update: Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects [Phase 3]
A Phase 3 trial comparing a Hib-MenC conjugate booster vaccine against Infanrix Hexa in 14-month-old children. The study has completed.
-
CLINICAL_TRIALS trial_result · 2016-09-07Clinical Trial Update: Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years [Phase 2]
A Phase 2 study evaluating a meningococcal A,C,W-135,Y conjugate vaccine given as a single dose in healthy adults aged 18-25 has completed.
-
CLINICAL_TRIALS trial_result · 2016-08-18Clinical Trial Update: Safety and Immunogenicity Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old [Phase 3]
A Phase 3 study evaluating safety and immunogenicity of the ACYW135 meningococcal polysaccharide vaccine in people aged 2-50; the trial stat…
-
CLINICAL_TRIALS trial_result · 2016-08-16Clinical Trial Update: Safety Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old [Phase 1]
Phase 1 safety study of ACYW135 meningococcal polysaccharide vaccine in individuals aged 2-50 years has completed. The study was sponsored b…
-
CLINICAL_TRIALS trial_result · 2016-06-14Clinical Trial Update: A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years [Phase 3]
A Phase 3 trial assessing lot consistency, safety, tolerability and immunogenicity of Pfizer's bivalent rLP2086 vaccine in healthy adolescen…
-
CLINICAL_TRIALS trial_result · 2016-02-23Clinical Trial Update: A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years. [Phase 3]
Phase 3 results report on safety, tolerability, and immunogenicity of the bivalent rLP2086 meningococcal vaccine in healthy adults aged 18 t…
-
CLINICAL_TRIALS trial_result · 2016-02-11Clinical Trial Update: Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children [Phase 2]
A Phase 2 trial evaluated the safety and immune response of a meningococcal vaccine in healthy children, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-01-20Clinical Trial Update: A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years [Phase 3]
This is a Phase 3B open-label study evaluating the safety, tolerability, and immunogenicity of the Novartis Meningococcal B Recombinant Vacc…